Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated February 15, 2023, reports on the vesting of Conditional Share Awards under the Share Value Plan and the subsequent sale of Ordinary Shares and American Depositary Shares (ADSs) by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them. The transactions occurred on February 14, 2023, relating to awards granted in 2020.
Key Financial Metrics
The filing does not provide corporate-level financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details specific equity transactions involving executive compensation.
| Individual | Role | Instrument | Transaction Type | Volume | Price |
|---|---|---|---|---|---|
| Mr D Jackson (PCA of Ms S Jackson) | SVP, Global Communications | Ordinary Shares | Vesting | 6,330 | £0.00 |
| Mr D Jackson (PCA of Ms S Jackson) | SVP, Global Communications | Ordinary Shares | Sale (Tax) | 2,976 | £14.7819 |
| Ms S Ramakrishnan | Chief Digital and Technology Officer | ADSs | Vesting | 5,740 | $0.00 |
| Ms S Ramakrishnan | Chief Digital and Technology Officer | ADSs | Sale (Tax) | 3,063 | $35.9588 |
| Dr T Wood | Chief Scientific Officer | Ordinary Shares | Vesting | 8,314 | £0.00 |
| Dr T Wood | Chief Scientific Officer | Ordinary Shares | Sale (Tax) | 3,908 | £14.7819 |
| Ms V Whyte | Company Secretary | Ordinary Shares | Vesting | 10,050 | £0.00 |
| Ms V Whyte | Company Secretary | Ordinary Shares | Sale (Tax) | 4,724 | £14.7819 |
Material Changes
The filing does not report material changes to the company's financial position, operations, or strategy compared to prior periods. It serves solely as a regulatory notification of insider equity movements.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies. The transactions were executed to meet tax liabilities arising from the vesting of awards conditional on continued employment.
Key Facts for Investor Verification
- Verify the total number of shares vested versus sold to determine the net increase in executive holdings.
- Confirm the market price of GSK Ordinary Shares and ADSs on February 14, 2023, to validate the transaction prices listed (£14.7819 and $35.9588).
- Review the 2020 Share Value Plan terms to understand the vesting schedule and performance conditions met by these executives.
- Note that the filing does not impact GSK's consolidated financial statements or cash flow.